Advertisement

Cancer Causes & Control

, Volume 10, Issue 4, pp 277–284 | Cite as

Use of oral contraceptives and endometrial cancer risk (Sweden)

  • Elisabete Weiderpass
  • Hans-Olov Adami
  • John A. Baron
  • Cecilia Magnusson
  • Anders Lindgren
  • Ingemar Persson
Article

Abstract

Objectives: To estimate the magnitude and persistence of the protective effect of use of combined oral contraceptives (COCs) and endometrial cancer risk.

Methods: We performed a nation-wide, population-based case–control study among postmenopausal women aged 50–74 years in Sweden, which included 709 subjects with incident, histopathologically verified endometrial cancer, and 3,368 controls with an intact uterus. We used unconditional logistic regression to calculate odds ratios as estimates of relative risks.

Results: Use of any sort of oral contraceptive decreased risk for endometrial cancer by 30%, while progestin-only pills reduced risk more markedly. For COCs the reduction in risk was noticeable following 3 or more years of use (OR 0.5, 95% CI 0.3–0.7), and increased with duration of intake, reaching 80% lower risk after 10 years of use. The protective effect of COC use was similar for all degrees of tumor differentiation and invasiveness, and remained for at least 20 years after cessation of use. Subsequent use of hormone replacement did not modify these protective effects.

Conclusions: We conclude that COC use confers a long-lasting protection against endometrial cancer risk which is particularly marked for long-term users.

combined oral contraceptives endometrial neoplasms Sweden 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    International Agency for Research on Cancer (1999) Some Hormones, Postmenopausal Hormone Therapy, and Hormonal Contraception. Lyon: IARC Monograph on the evaluation of carcinogenic risks to humans, vol. 72 (in press).Google Scholar
  2. 2.
    Breslow NE, Day NE (1980) Statistical Methods in Cancer Research. vol. 1: The Analysis of Case-Control Studies. Lyon: International Agency for Research on Cancer, pp. 192-246.Google Scholar
  3. 3.
    Weiderpass E, Baron JA, Adami HO, et al. (1999) Low potency estrogen formulations and risk for endometrial cancer. Lancet (in press).Google Scholar
  4. 4.
    Gray LA Sr, Christopherson WM, Hoover RN (1977) Estrogens and endometrial carcinoma. Obstet Gynecol 49: 385-389.Google Scholar
  5. 5.
    Weiss NS, Sayvetz TA (1980) Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302: 551-554.Google Scholar
  6. 6.
    Kaufman DW, Shapiro S, Slone D, et al. (1980) Decreased risk of endometrial cancer among oral contraceptive users. N Engl J Med 303: 1045-1048.Google Scholar
  7. 7.
    Hulka BS, Chambless LE, Kaufman DG, Fowler WC Jr, Greenberg BG (1982) Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247: 475-477.Google Scholar
  8. 8.
    Kelsey JL, Livolsi VA, Holford TR, et al. (1982) A case-control study of cancer of the endometrium. Am J Epidemiol 116: 333-342.Google Scholar
  9. 9.
    La Vecchia C, Francheschi S, Decarli A, Gallus G, Tognoni G (1984) Risk factors for endometrial cancer in different ages. J Natl Cancer Inst 73: 667-671.Google Scholar
  10. 10.
    La Vecchia C, Decarli A, Fasoli M, et al. (1986) Oral contraceptives and cancers of the breast and of the female genital tract: interim results from a case-control study. Br J Cancer 54: 311-317.Google Scholar
  11. 11.
    Pettersson B, Adami H-O, Bergström R, Johansson EDB (1986) Menstruation span — a time-limited risk factor for endometrial cancer. Acta Obstet Gynecol Scand 65: 247-255.Google Scholar
  12. 12.
    Centers for Disease Control and the National Institute of Child Health and Human Development (1987) The Cancer and Steroid Hormone Study. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257: 796-800.Google Scholar
  13. 13.
    World Health Organization (WHO) Collaborative Study of Neoplasia and Steroid Contraceptives (1988) Endometrial cancer and combined oral contraceptives. Int J Epidemiol 17: 263-269.Google Scholar
  14. 14.
    Koumantaki Y, Tzonou A, Koumantakis E, Kaklamani E, Aravantinos D, Trichopoulos D (1989) A case-control study of cancer of endometrium in Athens. Int J Cancer 43: 795-799.Google Scholar
  15. 15.
    Levi F, La Vecchia C, Gulie C, et al. (1991) Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control 2: 99-101.Google Scholar
  16. 16.
    Rosenblatt KA, Thomas DB (1991) The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer. Int J Cancer 49: 870-874.Google Scholar
  17. 17.
    Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF Jr (1991) A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 19: 38-43.Google Scholar
  18. 18.
    Jick SS, Walker AM, Jick H (1993) Oral contraceptives and endometrial cancer. Obstet Gynecol 82: 931-935.Google Scholar
  19. 19.
    Stanford JL, Brinton LA, Berman ML, et al. (1993) Oral contraceptives and endometrial cancer: do other risk factors modify this association? Int J Cancer 54: 243-248.Google Scholar
  20. 20.
    Voigt LF, Deng Q, Weiss NS (1994) Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer. Cancer Causes Control 5: 227-233.Google Scholar
  21. 21.
    Vessey MP, Painter R (1995) Endometrial and ovarian cancer and oral contraceptives — findings in a large cohort study. Br J Cancer 71: 1340-1332.Google Scholar
  22. 22.
    Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A (1983) The epidemiology of endometrial cancer in young women. Br J Cancer 47: 749-756.Google Scholar
  23. 23.
    Key TJA, Beral V (1992) Sex hormones and cancer. In: Vainio H, Magee PN, McGregor DB, Mc Michel AJ, eds. Mechanisms of Carcinogenesis in Risk Identification. Lyon: International Agency for Research on Cancer, pp. 225-269.Google Scholar
  24. 24.
    Gurpide E. (1991) Endometrial cancer: biochemical and clinical correlates. J Natl Cancer Inst 83: 405-416.Google Scholar
  25. 25.
    Hsueh AJ, Peck EJ Jr, Clark JH (1975) Progesterone antgonism of the oestrogen receptor and estrogen-induced uterine growth. Nature 254: 337-339.Google Scholar
  26. 26.
    Tseng L, Gurpide E (1975) Effects of progestins on estradiol receptor levels in human endometrium. J Clin Endocrinolol Metab 41: 402-404.Google Scholar
  27. 27.
    Graham JD, Clarke CL (1997) Physiological action of progesterone in target tissues. Endocrinol Rev 18: 502-519.Google Scholar
  28. 28.
    Grady D, Gebretsadik T, Ernster V, Pettiti D (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304-313.Google Scholar
  29. 29.
    Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of estrogen combined cyclic progestagen therapy in postmenopausal women. Lancet 349: 458-461.Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Elisabete Weiderpass
    • 1
  • Hans-Olov Adami
    • 1
    • 2
  • John A. Baron
    • 3
  • Cecilia Magnusson
    • 1
  • Anders Lindgren
    • 4
  • Ingemar Persson
    • 1
  1. 1.Department of Medical EpidemiologyKarolinska InstitutetStockholmSweden
  2. 2.Department of Epidemiology and Harvard Center for Cancer PreventionHarvard UniversityBostonUSA
  3. 3.Dartmouth Medical SchoolHanoverUSA
  4. 4.Department of PathologyFalun HospitalFalunSweden

Personalised recommendations